Difference between revisions of "Isatuximab (Sarclisa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*3/2/2020: Approved in combination with pomalidomide and dexamethasone for adult patients with [[multiple myeloma]] who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. | *3/2/2020: Approved in combination with pomalidomide and dexamethasone for adult patients with [[multiple myeloma]] who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. | ||
| + | *3/31/2021: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory [[multiple myeloma]] who have received one to three prior lines of therapy. | ||
==Also known as== | ==Also known as== | ||
Revision as of 14:15, 1 April 2021
General information
Class/mechanism from NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 3/2/2020: Approved in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
- 3/31/2021: Approved in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
Also known as
- Code name: SAR-650984
- Generic name: isatuximab-irfc
- Brand name: Sarclisa